136
Participants
Start Date
January 13, 2022
Primary Completion Date
June 6, 2023
Study Completion Date
June 21, 2023
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
LEO Pharma Investigator, Cortland
LEO Pharma Investigator, Horseheads
LEO Pharma Investigator, Sanford
LEO Pharma Investigational Site, Hialeah
LEO Pharma Investigator, Birmingham
LEO Pharma Investigator, Birmingham
LEO Pharma Investigator, Bexley
LEO Pharma Investigator, Toledo
LEO Pharma Investigator, Detroit
LEO Pharma Investigator, Libertyville
LEO Pharma Investigator, Overland Park
LEO Pharma Investigator, Fort Smith
LEO Pharma Investigator, Tulsa
LEO Pharma Investigator, Frisco
LEO Pharma Investigator, Dallas
LEO Pharma Investigator, Webster
LEO Pharma Investigator, San Antonio
LEO Pharma Investigator, Centennial
LEO Pharma Investigator, Los Angeles
LEO Pharma Investigational Site, Inglewood
LEO Pharma Investigator, San Diego
LEO Pharma Investigator, San Diego
LEO Pharma Investigator, Santa Ana
LEO Pharma Investigator, Fountain Valley
LEO Pharma Investigator, Fremont
LEO Pharma Investigator, Portland
LEO Pharma Investigator, Farmington
LEO Pharma Investigator, Bangor
LEO Pharma Investigator, Portsmouth
Lead Sponsor
LEO Pharma
INDUSTRY